STEERLife is a speciality life sciences company that deploys it’s proprietary and disruptive technology platforms to change the way medicines are made and taken.
STEERLife’s patented processes result in differentiated and specialty products with enhanced convenience, compliance, bioavailability, efficacy and/or safety.
STEERLife’s continuous manufacturing program leverages its innovative technology to provide more efficient continuous and integrated manufacturing.
STEERLife— A STEER GROUP COMPANY
STEERLife is a part of the STEER Group. Founded in 1993 by Dr. Babu Padmanabhan, the STEER Group is committed to the design, creation and implementation of advanced materials platform technologies that effectively transform and functionalise materials in the field of pharmaceuticals, plastics, food & nutraceuticals, biomaterials and biorefining. Operating 5 global offices, 10 satellite offices, 3 Application Development Centers and supported by a talented workforce of over 500 engineers, scientists and technicians, STEER Group serves over 39 countries across the globe. STEER is driven by innovation and holds several patents along the length, breadth and depth of its proprietary platforms. With a vision to ‘STEER A NEW WORLD’, the group remains focused on the development of advanced platform technologies and processes to improve the quality of life and change the way people live, eat and stay healthy.
MD & CHIEF KNOWLEDGE OFFICER
A pharmacy graduate from BHU and a postgraduate from UK, Dr. Sen spent 11 years with Bristol-Myers Squibb in the UK in areas of pharmaceutical development, technology transfer, plant support, drug delivery systems and generic product development. Since his return to India in 1990, he has spent over 2 decades with leading Indian pharmaceutical companies, namely Ranbaxy and Lupin Limited. In these leadership positions, he is credited with driving the generic revolution from India. During an extensive career spanning more than 3 decades, Dr. Sen has been responsible for the development and approval of more than a 100 regulatory submissions and approvals for the US and EU markets namely in ANDAs, NDAs, INDs and NDDS. He has more than 50 patents to his name, a majority of which are commercially available products in global markets and has also been responsible for licensing a drug delivery technology-based product to an MNC.
Dr. Babu's journey began with a vision — to steer a new world. He has made significant contributions to the field of polymer processing. His work in designing processing section components has led to the development of intelligent compounding technology that has redefined pharmaceutical manufacturing. The fractional lobed processor (FLP) invented by him provides critical break-through in continuous granulation.
Mr. Dipak Chattaraj is the Ex-Chairman, Ranbaxy Pharmaceuticals Inc., U.S., and Ex-President (Corporate Development and Strategy), Ranbaxy Laboratories Ltd.
He retired from Ranbaxy in 2011 and now consults for the pharmaceutical industry in India as well as the United States. Dipak leads STEER America as Chairman.
Mr.Indu Bhushan, brings more than 2 decades of core pharmaceutical development experience to the table. With his contribution to more than 20 publications and patents, his current research activities in STEERLife focus on creating a difference to the way pharmaceuticals are manufactured and administered. Prior to STEERLife, he was associated with several leading multinational companies where he played a key role in setting up the facilities and resources for the development of generic and specialty pharmaceuticals.